Press Releases

Date Title
Summary ToggleNeothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat Printer Friendly Version SAN DIEGO , March 20, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced completion of subject enrollment for its Phase 2 proof of concept trial, LIPO-202-CL-31, for the
Summary ToggleNeothetics to Provide a Business Update and Release Fourth Quarter 2016 Financial Results Thursday, March 23, 2017 Printer Friendly Version SAN DIEGO , March 16, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today announced that it will provide a business update and release its fourth quarter 2016 financial results before the market opens on Thursday, March 23 , 2017.  To receive Neothetics' press releases and other investor